Research Paper Volume 16, Issue 15 pp 11553—11567

The deubiquitinating enzymes-related signature predicts the prognosis and immunotherapy response in breast cancer

class="figure-viewer-img"

Figure 1. External dataset validation and clinical correlation of DUBRI. The Kaplan-Meier survival curves were used to compare the high and low DUBRI groups in both the TCGA dataset (A) and the GEO external dataset (B). Univariate (C) and multivariate (D) Cox regression analysis was used to examine the relationship between DUBRI and other clinical characteristics. (E) Receiver Operating Characteristic (ROC) curves depicting the performance of DUBRI at 1, 3, and 5 years. (F) Receiver Operating Characteristic (ROC) curves comparing the performance of DUBRI with various clinical features at 1, 3, and 5 years. (G) Prognostic column line graphs for breast cancer patients. (H) The provided data present calibration curves depicting the likelihood of overall survival at 1, 3, and 5 years in the TCGA cohort.